The Association of liver Patients Care ( ALPC) is a non governmental organization founded in 1997 in Dakahliah- Egypt.
It provides free treatment , free investigation and free medications for poor liver patients ,and help their families.
It aims to raise the awareness of prevention of liver diseases by holding conferences , campaigns , seminars and public lectures . It also holds specialized workshops for doctors to raise their efficiency.
The Association of liver Patients Care ( ALPC) is a founding member of the European Liver Patients Association (ELPA) since June 2004, due to its scientific activities exchanged with European associations in many countries.
The association is establishing a hospital and institute of liver research to be number one in the Arabic Area. The hospital is located in Sherbin near Mansoura on 4 acres . The association contracted with ( Almokaweloon Alarab) to accomplish the project.
The final phase includes the outpatient clinics , the laboratories , the pharmacy , the Endoscope unit , Catheter injection unit and radiation unit (sonars – magnetic resonance – C . T scan ).
The association aims to obtain the best laboratories and to establish a Plague Unit for monitoring the progress of liver diseases spread in the area to put the appropriate prevention strategies.
The association aims to establish a liver transplant unit to help patients who seek cure from chronic liver diseases.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close